Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.

Oncotarget - 31 May 2016

Frink Robin E, Peyton Michael, Schiller Joan H, Gazdar Adi F, Shay Jerry W, Minna John D

Abstract excerpt

Telomerase was evaluated as a therapeutic oncotarget by studying the efficacy of the telomerase inhibitor imetelstat in non-small cell lung cancer (NSCLC) cell lines to determine the range of response phenotypes and identify potential biomarkers of response. A panel of 63 NSCLC cell lines was studied for telomere length and imetelstat efficacy in inhibiting colony formation and no correlation was found with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Mice, Inbred NOD

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Niacinamide

Share to Oligonucleotides

Share to Telomere Homeostasis

Share to Telomere Shortening

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 27192120
DOI: 10.18632/oncotarget.9335
PMCID: PMC5077965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.PMID 27192120Read ↗

Telomerase in hematologic malignancies.Semantic proximity Read ↗

Telomerase-based Cancer Therapeutics: A Review on their Clinical TrialsSemantic proximity Read ↗

Targeting the Limitless Replicative Potential of Cancer: The Telomerase/Telomere PathwaySemantic proximity Read ↗

Inhibition of telomerase limits the growth of human cancer cells.Semantic proximity Read ↗

The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic ImplicationsSemantic proximity Read ↗

Transient telomerase inhibition alters cell cycle kineticsSemantic proximity Read ↗

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.Semantic proximity Read ↗

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancerSemantic proximity Read ↗

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancerSemantic proximity Read ↗

High-Throughput RNAi Screening Reveals Novel Regulators of TelomeraseSemantic proximity Read ↗

Telomerase Activity in Small-Cell and Non-Small-Cell Lung CancersSemantic proximity Read ↗

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.